Tempus won clearance for software that reads a routine heart tracing for signs of undiagnosed mitral regurgitation.
Machine learning improved three-year outcome predictions for transthyretin amyloid cardiomyopathy.
An AI trained on ECGs identifies vessel-specific coronary blockages and improves risk reclassification before imaging.